27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing.
Pfizer Inc. (NYSE:PFE) reported disappointing fourth-quarter earnings and Amgen, Inc. (NASDAQ:AMGN) guided 2020 below consensus, while Eli Lilly And Co (NYSE:LLY) managed to outperform expectations.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The week continued to see coronavirus-related spikes, with Cleveland BioLabs, Inc. (NASDAQ:CBLI), NanoViricides, Inc. (NASDAQ:NNVC), Vir Biotechnology, Inc. (NASDAQ:VIR) and Vaccinex, Inc. (NASDAQ:VCNX) among the stocks riding on the momentum.
Acceleron Pharma Inc (NASDAQ:XLRN) was one of the standout gainers of the week, thanks to a positive midstage clinical readout.
The much-anticipated FDA verdict on Aimmune Therapeutics Inc's (NASDAQ:AIMT) peanut allergy drug Palforzia came through in the week, with the regulatory agency greenlighting the drug.
Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020
Turning ahead to the unfolding week, the following are key catalysts that could create a ripple in the biotech space.
Conferences
- 2nd International Scientific & Clinical Congress on Spinal Muscular Atrophy: Feb. 5-7 in Paris, France
- The European Association for Hemophilia and Allied Disorders, or EAHAD, 2020 Congress: Feb. 5-7 in Hague, Netherlands
- ASCO-SITC Clinical Immuno-Oncology Symposium: Feb. 6-8 in Orlando, Florida
- Angiogenesis, Exudation, and Degeneration 2020: Feb. 8 in Miami, Florida
Clinical Readouts
Forty Seven Inc (NASDAQ:FTSV) is due to present at the ASCO-SITC Symposium Phase 1b data for magrolimab + avelumab in ovarian cancer.
Jounce Therapeutics Inc (NASDAQ:JNCE) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors. (Feb. 6)
Catalyst Biosciences Inc (NASDAQ:CBIO) is scheduled to present at the EAHAD Congress Phase 2b data for dalcinonacog alfa in hemophilia B. (Feb. 7)
Kodiak Sciences Inc (NASDAQ:KOD) is due to present at the Angiogenesis, Exudation, and Degeneration 2020with Phase 1b data for KSI-301 in diabetic macular edema (Feb. 8)
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Adverum Biotechnologies Inc (NASDAQ:ADVM) will present at the Angiogenesis, Exudation, and Degeneration 2020 with Phase 1 data for ADVM-022 in wet age-related macula degeneration. (Feb. 8)
Earnings
Monday
- Catalent Inc (NYSE:CTLT) (before the market open)
- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (after the close)
Tuesday
- Zimmer Biomet Holdings Inc (NYSE:ZBH) (before the market open)
- Haemonetics Corporation (NYSE:HAE) (before the market open)
- BIO-TECHNE Corp (NASDAQ:TECH) (before the market open)
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) (after the close)
- Gilead Sciences, Inc. (NASDAQ:GILD) (after the close)
- Qiagen NV (NYSE:QGEN) (after the close)
Wednesday
- Merck & Co., Inc. (NYSE:MRK) (before the market open)
- Boston Scientific Corporation (NYSE:BSX) (before the market open)
- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) (after the close)
- Cardiovascular Systems Inc (NASDAQ:CSII) (after the close)
- Misonix Inc (NASDAQ:MSON) (after the close)
- SurModics, Inc. (NASDAQ:SRDX) (after the close)
Thursday
- ABIOMED, Inc. (NASDAQ:ABMD) (before the market open)
- Bristol-Myers Squibb Co (NYSE:BMY) (before the market open)
- Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) (before the market open)
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) (before the market open)
- Twist Bioscience Corp (NASDAQ:TWST) (after the close)
- Anavex Life Sciences Corp (NASDAQ:AVXL) (after the close)
- Pacific Biosciences of California (NASDAQ:PACB) (after the close)
- Enanta Pharmaceuticals Inc (NASDAQ:ENTA) (after the close)
- Myriad Genetics, Inc. (NASDAQ:MYGN) (after the close)
- Seattle Genetics, Inc. (NASDAQ:SGEN) (after the close)
- Natus Medical Inc (NASDAQ:NTUS) (after the close)
- LeMaitre Vascular Inc (NASDAQ:LMAT) (after the close)
- Ligand Pharmaceuticals Inc. (NASDAQ:LGND) (after the close)
Friday
- AbbVie Inc (NYSE: ABBV (before the market open)
- Meridian Bioscience, Inc. (NASDAQ: VIVO (before the market open)
IPOs
Beam Therapeutics plans to offer 6.25 million shares in an IPO, with the offering expected to be priced between $15 and $17. The company, which is engaged in developing therapies based on single-base gene editing, has applied for listing its shares on the Nasdaq under the ticker symbol "BEAM."
Contract research organization PPD is planning a 60-million-share IPO to be priced in the range of $24-$27. The shares are to be listed on the Nasdaq under the ticker symbol "PPD."
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.